AUTO-URINE INJECTIONS AT THE WILLIAM HITT CENTER IN MEXICO
ALSO: UROTHERAPY FOR PATIENTS WITH CANCER BY JOSEPH ELDOR, MD
http://www.williamhittcenter.com
http://www.csen.com/cancer-urotherapy
http://www.salvationscience.com

As clinical studies have demonstrated, oral urine or urea can be just as
effective for non-emergency cases as injected urine. And, as doctors themselves
have commented, oral urine therapy can be used at safely and effectively at home
without the unnecessary cost- and inconvenience of a doctor's office visit,
while injections can be reserved for those with urgent needs under a doctor's
care.

However, if your situation is extremely severe, urine injections can
definitely be of benefit. Dr. William Hitt (whom I mentioned earlier)
runs two urine therapy cimics in Mexico and has administered hundreds
of thousands of injections to severely HI patients with remarkable
success.

Can too much uric acid or urea be harmful?

As several of the dinical studies showed, urea, even in large doses,
has been found to be harmless to the body, Researchers, (Urea - New
Use of An Old Agent), reported that they safely administered urea
daily to several patients for a period ranging from several day» to
weeks, and in some cases, even several months, without any side
effects, in doses ranging from 100 mg. per kilogram of body weight to
as much as 600 mg. per kilogram of body weight.
------------------

WILLIAM HITT CENTER
http://www.williamhittcenter.com

Call us Mon-Fri 9-5, Sat 9-2 PST
1-888-671-9849 or 1-888-269-7303

AUTO-URINE INJECTIONS: "ANTIGEN RECEPTOR VACCINATION"

This form of therapy is extensively used at the William Hitt Center. It is
helpful in most diseases, for the reasons explained below.

Antigen Receptor Vaccination takes advantage of the immunologically important
substances found in urine. Urine is nothing but the product of filtration of the
blood by the kidneys. In other words, everything found in urine—everything—was
circulating through your brain and heart just minutes before showing up in the
bladder. The important part is that immune proteins (molecules your body uses to
control immune reactions) arrive in large quantities in the urine, after leaving
the bloodstream. These proteins (explained below) include antigen receptors, T
cell suppressor factors, Interferon gamma, Interleukin 1 and others.

Antigen Receptor Vaccination is performed by obtaining a sample of a patient's
fresh urine, adding a small amount of the anesthetic lidocaine, then injecting
3-10 cc of the solution into the muscle tissue. To prevent possible bacterial
infection, the solution passes through a sterilizing syringe filter prior to
injection. Injection can be done everyday or once a week, depending on the
disease being treated.

How Antigen Receptor Vaccination Works

Allergy

Allergic reactions occur when an antigen (the substance causing the allergy,
like cat dander or ragweed) is brought into the body. The antigen triggers an
antigen receptor—an antibody-like protein that is designed to let the body know
when the antigen shows up. So, a person who is allergic to cats has many antigen
receptors ready to go and waiting for exposure to cats. Once the antigen
receptor has been triggered, it signals the "B cell" to start production of
antibodies and the allergic reaction, while the receptor itself is jettisoned
into the circulation where many of them will eventually go to the urine.

Injecting these spent antigen receptors back into the patient's muscle and fat
tissue has two effects. The first is to cause "T suppressor" cells to be formed,
which helps calm down the allergic reaction very quickly. The other effect is
the body making antibody to the injected antigen receptors, which over a few
weeks of weekly injections will allow antibodies to cover up the antigen
receptors on the "B cells" and thereby cause long-term suppression of allergy.

Chemical sensitivity

These reactions are run mostly by cells called neutrophils, cells that absorb
foreign substances. Other cell types and certain cell hormones can sensitize
neutrophils to the point where they become "allergic" to a given substance (like
a chemical), causing them to overreact and suffer damage and destruction. The
person experiences this neutrophil sensitization as chemical sensitivity.

Antigen Receptor Vaccination suppresses these reactions by turning off
neutrophils' own excess reactivity and by suppressing production of the cell
hormones responsible for sensitizing the neutrophils.

Viral disease

Antigen Receptor Vaccination is very helpful in viral disease. It works by
stimulating the action of interferons, particularly Interferon gamma.
Interferons stop viruses from reproducing, and stop virus-infected cells from
multiplying. Interleukin 1, another cell hormone involved in antiviral activity,
is also stimulated in this process.

Autoimmune disease

These diseases respond very well to Antigen Receptor Vaccination through a
combination of the above processes.

Antigen Receptor Vaccination, properly performed, is very safe for patients of
any age or condition. It has been used for many years on thousands of patients
with no evidence of short- or long-term problems.
---------------------------

UROTHERAPY FOR PATIENTS WITH CANCER
http://www.csen.com/cancer-urotherapy

Joseph Eldor, MD

Theoretical Medicine Institute
P.O.Box 12142, Jerusalem, 91120,Israel
E-mail: a1b2c3d4@...

Subcutaneous urine injections was practiced in 1912 by
Duncan (1) from New York under the name of auto-pyotherapy
for urinary infections, and in 1919 by Wildbolz (1) from
Bern for diagnostic purposes. Cimino (2) from Palermo
reported in 1927 on the use of auto uro-therapy for urinary
infections. Rabinowitch (3) in 1931 described this
auto-urine therapy for gonarthritis. Jausion et al. (4)
used this kind of therapy in 1933 for desensitization and
endocrinological problems. They treated with auto urotherapy
injections patients who suffered from migraine, pruritus,
asthma, urticaria, eczema, psoriasis, etc. Day (5)in 1936
treated patients with acute and subacute glomerulonephritis
by injection of an autogenous urinary extract. Sandweiss,
Saltzstein and Farbman (6) reported in 1938 that an extract
from urine of pregnant women has a prophylactic and
therapeutic effect on experimental ulcers in dogs. Shortly
thereafter the same group noted that an extract from urine
of normal women has a similar beneficial effect (7).

In 1926 Seiffert first described the construction of ileal
loop conduits for urinary diversion (8). Bricker in the
1950s popularized the use of the ileal loop as a means of
supravesical urinary diversion following exenteration for
pelvic malignancy in adults (9). Ureterosigmoidostomy as a
means of urinary diversion was used widely from 1920 to
1955. It was this type of implant which Hammer first
reported in 1929 associated with tumor (10).
Peyer`s patches are immunocompetent lymphoid organs which
participate in intestinal immune responses (11). Epithelial
cells within the crypts of the small bowel are one of the
fastest dividing cells in the body and yet they show one of
the lowest rate of malignant transformation (12). Stem cells
in the mucosa of the small bowel can divide every 8 to 12
hours (13). Tapper and Folkman (14) demonstrated that
exposure of intestinal segments to urine causes marked
lymphoid depletion in the segments. These studies give
additional support to the idea that a lymphocyte suppressive
factor exist in urine (15). The continued presence of urine
bathing the intestinal mucosa appears to locally inhibit
regeneration of the Peyer`s patches.

Starkey et al. (16) detected in human urine a material that
is biologically and immunologically similar to epidermal
growth factor that causes proliferation and keratinization
of epidermal tissues.

The increased susceptibility of the colon to cancer
associated with the existence of an implanted ureter has
been theorized to relate to 3 factore: 1. The role of the
urine in the colon (17,18). 2. The mechanical effect of the
fecal stream on the stoma (19). 3. The age of the
anastomosis (20). Adenocarcinoma of the colon mucosa is a
recognized complication of ureterosigmoidostomy. The tumor,
which develops adjacent to the junction of the ureter with
the bowel, occurs 500 times as often as in the population at
large and, in children so operated , 7,000 times as often as
in all persons under age 25. The latency period is 5 to 50
years (17,21-23).

It is common knowledge that malignant tumors may disappear
spontaneously although very infrequently (24-26). Usually it
is accepted that this could be due at least partly to an
immunological reaction (27,28). Renal adenocarcinoma is one
of the cancer types in which such spontaneous regressions
have been described most frequently (24,26).
Urinary extracts from patients with aplastic anemia (29) and
idiopathic thrombocytopenic purpura (30) are capable of
stimulating megakaryocyte colony growth in culture, and when
injected into rats could also induce thrombocytosis in
peripheral blood and megakaryocytosis in the spleens of
these animals. Stanley et al. (31) demonstrated that rabbits
immunized with human urine concentrates from leukemic
patients developed antibody which neutralized the mouse bone
marrow colony stimulating factor in human urine and human
serum.

Urotherapy is suggested as a new kind of immunotherapy for
cancer patients. Unlike the clonal immunotherapy the urine
of the cancer patients contain the many tumor antigens which
constitute the tumor. Oral auto-urotherapy will provide the
intestinal lymphatic system the tumor antigens against which
they may produce antibodies due to non-self recognition.
These antibodies may be transpierced through the blood
stream and attack the tumor and its cells.

References:

1. Jausion H. Sur l'auto-ouro-therapie. Journal D'Urologie
1935;39:58-59
2. Cimino T. Premiers essais de vaccine-proteine-therapie
des infections non gonococciques ni tuberculeuses des voies
urinaires a l'aide des injections sous-cutanees de l'urine
purulente du sujet, sterilisee par l'ebullition
(ouro-therapie). Rivista Sanitaria 1927;186
3. Rabinowitch IM. Auto-urine-therapy in gonarthritis.
Vratchebnaia gazeta 1931;35:677-8
4. Jausion H, Giard R, Martinaud G. L'auto-ouro-therapie.
La Presse Medicale 1933;76:1467-1470
5. Day HB. Treatment of glomerulonephritis by antigen.
Lancet 1936;1456-9
6. Sandweiss DJ, Saltzstein HC, Farbman AA. The prevention
or healing of experimental ulcer in Mann-Williamson dogs
with the Anterior-Pituitary-Like hormone (Antuitrin-S). Am J
Dig Dis 1938;5:24-30
7. Sandweiss DJ, Saltzstein HC, Farbman AA. The relation of
sex hormones to peptic ulcer. Am J Dig Dis 1939;6:6-12
8. Seiffert L. Die "Darn-Siphonblase". Arch fur Klin Chir
1935;183:569
9. Bricker EM. Bladder substitution after pelvic
evisceration. Surg Clin North Am 1950;30:1511
10. Hammer E. Cancer du colon sigmoide dix ans apres
implantation des ureteres d'une vessie exstrophiee. J Urol
Nephrol 1929;28:260
11. Miller-Schoop JW, Good RA. Functional studies of Peyer`s
patches: Evidence for their participation in intestinal
immune responses. J Immunol 1975;144:1757
12. Barclay THC, Schapira DV. Malignant tumors of the small
bowel. Cancer 1983;51:878-881
13. Loeffler M, Stein R, Wichmann HE, Potten CS, Kaur P,
Chwalinski S. Intestinal cell proliferation. I. A
comprehensive model of steady-state proliferation in the
crypt. Cell Tissue Kinet 1986;19:627-645
14. Tapper D, Folkman J. Lymphoid depletion in ileal loops:
Mechanism and clinical implications. J Pediatr Surg
1976;11:871-880
15. Wilson WEC, Kirkpatrick CH, Talmage DW. Suppression of
immunologic responsiveness in uremia. Ann Intern Med
1965;62:1
16. Starkey RH, Cohen S, Orth DN. Epidural growth factor:
Identification of a new hormone in human urine. Science
1975;189:800-802
17. Urdaneta LF, Duffell D, Creevy CD, Aust JB. Late
development of primary carcinoma of the colon following
ureterosigmoidostomy: report of three cases and literature
review. Ann Surg 1966;164:503-13
18. Harguindey SS, Colbeck RC, Bransome ED JR.
Ureterosigmoidostomy and cancer: new observations (letter).
Ann Intern Med 1975;83:833
19. Rivard JY, Bedard A, Dionne L. Colonic neoplasms
following ureterosigmoidostomy. J Urol 1975;113:781-6
20. Carswell JJ III, Skeel DA, Witherington R, Otken LB Jr.
Neoplasia at the site of ureterosigmoidostomy. J Urol
1976;115:750-2
21. Lasser A, Acosta AE. Colonic neoplasms complicating
ureterosigmoidostomy. Cancer 1975;35:1218-22
22. Sooriyaarachchi GS, Johnson RO, Carbone PP. Neoplasms of
the large bowel following ureterosigmoidostomy. Arch Surg
1977;112:1174-7
23. Eraklis AJ, Folkman MJ. Adenocarcinoma at the site of
ureterosigmoidostomies for exstrophy of the bladder. J
Pediatr Surg 1978;13:730-4
24. Everson T. Spontaneous regression of cancer. Ann NY Acad
Sci 1964;114:721-35
25. Stephenson H, Delmez J, Renden D, Kimpton R, Todd P,
Charron T, Lindberg D. Host immunity and spontaneous
regression of cancer evaluated by computerized data
reduction study. Surg Gynecol Obstet 1971;133:649-55
26. Cole W. Spontaneous regression of cancer: The metabolic
triumph of the host? Ann NY Acad Sci 1974;230:111-41
27. Burnet F. Immunological aspects of malignant disease.
Lancet 1967;II:1171-4
28. Droller M. Immunotherapy and genitourinary neoplasia.
Urol Clin N Am 1980;7:831-46
29. Enomoto K, Kawakita M, Kishimoto S, Katayama N, Miyake
T. Thrombopoiesis and megakaryocyte colony stimulating
factor in the urine of patients with aplastic anemia. Br J
Haematol 1980;45:551-556
30. Kawakita M, Enomoto K, Katayama N, Kishimoto S, Miyake
T. Thrombopoiesis and megakaryocyte colony stimulating
factors in the urine of patients with idiopathic
thrombocytopenic purpura. Br J Haematol 1981;48:609-615
31. Stanley ER, McNeill TA, Chan SH. Antibody production to
the factor in human urine stimulating colony formation in
vitro by bone marrow cells. Br J Haematol 1970;18:585-590

http://www.williamhittcenter.com
http://www.csen.com/cancer-urotherapy
http://www.salvationscience.com
*****************************************************